PI Industries said exports continue to operate in a challenging environment. The company plans to launch 4-5 new molecules in FY27, while its pharma business remains focused on accelerating growth across Brazil, Mexico, Europe and the US.
PI Industries said exports continue to operate in a challenging environment. The company plans to launch 4-5 new molecules in FY27, while its pharma business remains focused on accelerating growth across Brazil, Mexico, Europe and the US.